Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt, Cepheid Ally for HPV Testing in Latin America

NEW YORK (GenomeWeb) – Novacyt and Cepheid have signed an agreement to introduce a complete human papillomavirus diagnostics system to Latin America.

Under the terms of the three-year, non-exclusive agreement, Cepheid will distribute Novacyt's NOVAprep vial, media, and cervical sample collection device in the region. These will be used in conjunction with the Cepheid Xpert HPV test, either as a primary cervical cancer screening assay or for reflex cytology.

The alliance will target 18 countries in Latin America, an area which has one of the highest incidence rates of cervical cancer in the world, estimated to be 20 to 80 per 100,000 women per year.

"The combination of NOVAprep’s proprietary sample collection and preparation capability together with Cepheid's diagnostic system positions us well for growth in Latin America," Novacyt CEO Graham Mullis said in a statement. "Our unique approach will provide significant benefits to patient risk stratification and we look forward to working with Cepheid in this new market and region for Novacyt."

The Xpert HPV test is CE marked and was launched in Europe in 2014. 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.